2026-04-14T08:23:23Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1750672025-12-05T12:35:16Zcom_2072_1057col_2072_478916col_2072_478917
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19
Barbui, Tiziano
Stefano, Valerio De
Álvarez Larrán, Alberto
Iurlo, Alessandra
Masciulli, Arianna
Carobbio, Alessandra
Ghirardi, Arianna
Ferrari, Alberto
Cancelli, Valeria
Elli, Elena Maria
Andrade Campos, Marcio Miguel
Gasior Kabat, Mercedes
Kiladjian, Jean-Jacques
Palandri, Francesca
Benevolo, Giulia
Garcia Gutierrez, Valentin
Fox, Maria Laura
Foncillas, Maria Angeles
Morcillo, Carmen Montoya
Rumi, Elisa
Osorio, Santiago
Papadopoulos, Petros
Bonifacio, Massimiliano
Quiroz Cervantes, Keina Susana
Serrano, Miguel Sagues
Carreño Tarragona, Gonzalo
Sobas, Marta Anna
Lunghi, Francesca
Patriarca, Andrea
Elorza, Begoña Navas
Angona, Anna
Mazo, Elena Magro
Koschmieder, Steffen
Carli, Giuseppe
Cuevas, Beatriz
Hernandez Boluda, Juan Carlos
Abadia, Emma Lopez
Xicoy Cirici, Blanca
Guglielmelli, Paola
Garrote i Ordeig, Marta
Cattaneo, Daniele
Daffini, Rosa
Cavalca, Fabrizio
Bellosillo, Beatriz
Benajiba, Lina
Curto Garcia, Natalia
Bellini, Marta
Betti, Silvia
Harrison, Claire
Rambaldi, Alessandro
Vannucchi, Alessandro Maria
Leucèmia mieloide
Trombosi
COVID-19
Myeloid leukemia
Thrombosis
COVID-19
In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (-23.3%, p < 0.0001) than in PV (-16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs.
2021-03-15T12:05:26Z
2021-03-15T12:05:26Z
2021-02-01
2021-03-11T11:57:40Z
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
https://hdl.handle.net/2445/175067
33563901
eng
Reproducció del document publicat a: https://doi.org/10.1038/s41408-021-00417-3
Blood Cancer Journal, 2021, vol. 11
https://doi.org/10.1038/s41408-021-00417-3
info:eu-repo/grantAgreement/EC/H2020/945406/EU//HARMONY PLUS
cc by (c) Barbui et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
11 p.
application/pdf
Springer Nature
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))